Endometrial Receptivity and Success Rate of IVFNCT01809509
Pilot Study on Molecular Quantitation and Sequencing of Endometrial Cytokines Gene Expression and Their Effect on the Outcome of In-vitro Fertilization (IVF) Cycle
An observational study of Endometrial Receptivity and Success Rate of IVF, run by Cairo University at 2 sites in Egypt.
Trial summary
Pilot study on molecular quantitation and sequencing of endometrial cytokines gene expression and their effect on the outcome of in-vitro fertilization (IVF) Cycle Read more about this study
- Who is it for?
- Ages 23 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Endometrial Receptivity and Success Rate of IVF
- What is being tested?
- Endometrial biopsy
- Type of treatment
- Surgery or procedure
- How many people
- 15 participants
- Where
- 2 sitesEgypt
- Study dates
- Jan 2012to Nov 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 23 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: those under going IVF using standard protocol
Who may be able to join
- FSH LESS THAN 10 ,
Who cannot join
- NO SEVER MALE FACTOR no endometriosis , DM or previous uterine surgery .
Trial locations and contacts
2 sites in 1 country.
About this study
Official title: A Prestudy of Impact of Cytokines and Gene Expression on Outcome of IVF
Pilot study on molecular quantitation and sequencing of endometrial cytokines gene expression and their effect on the outcome of in-vitro fertilization (IVF) Cycle
Read the detailed description
The study will be performed
in the Cairo IVE Unit; Faculty of medicine Cairo University on 15 cases. Inclusion criteria: age 23 -35, FSH less than 10 no previous uterine operations, no history of poor response in previous IVF no sever male factor no endometriosis and uterine factor are excluded . no diabetes mellitus and antral follicle count (AFC) > 5 undergoing IVF using standard long protocol.
All patients will give their informed consent to participate in the study. Endometrial tissue samples will be taken on the day of oocyte retrieval using soft suction plastic catheter. The menstrual blood of 10 women with regular menstrual cycles and with no apparent endometrial dysfunction was taken as control samples. The study protocol and informed consents were approved by the Human Ethics Committee of IVF department .of Kasar Ini hospital
Total RNA isolation: Endometrial biopsies and menstrual control blood will be lysed by RLT buffer (QIAGEN, Germantown, MD). The lysates further prepared for total RNA extraction using the RNeasy mini kit (QIAGEN, Germantown, MD) according to the manufacturer's instructions. The RNA extract stored at -80ºC until future use. RNA purity, yield, and concentration will be determined through dual spectrophotometry (Beckman, USA), and 1μg of RNA run on a 1% agarose gel (Roche, Castle Hill, Australia) to ensure integrity of the RNA. Quantitative RT-PCR (qRT-PCR): Reverse transcriptase (RT) reaction mixture using High Capacity Reverse Transcriptase kit (Applied Biosystems, USA) containing: 1 μg total RNA from each sample for cDNA synthesis, 0.5 μg random primer, 5×RT buffer, 2.5 mmol/L dNTP, 20 U RNase inhibitor and 200 U MMLV reverse transcriptase in a total volume of 25 μl was incubated at 37ºC for 60 minutes, then heated to 95 ºC for 5 minutes to inactivate MMLV. RT will be followed by qPCR, 50 ng of cDNA were added to 5 X Fast-Start SYBR green master mix with Rox (Roche Diagnostics, Indianapolis, IN) and 200 ng of primer mix (Sigma). The reaction will be carried out in micro optical plates (Applied Biosystems) and analyzed using StepOne real-time 203 PCR system (Applied Biosystems). The PCR running method was as follows: 10 minutes at 950C for enzyme activation followed by 40 cycles of 15 seconds at 950C, 20 seconds at 550C and 30 second at 720C for the amplification step. The primers used in the qRT-PCR evaluation specific for target genes (table 1). Relative mRNA expression will be calculated by the comparative cycle threshold method . as outlined in the manufacturer's user manual with GAPDH house-keeping gene. The fluorescence was plotted versus PCR cycle number for reaction and each sample indicated. Serum hormonal levels assay: FSH, LH and E2 were estimated by ELISA according to instructions of manufacturers. DNA purification and sequencing analysis: IL-11 and LIF genes analyzed by direct sequencing of the PCR products using SEQr kit. (Applied Biosystems), according to manufacturer's protocol. PCR products will be purified using the QIAquick Gel Extraction Kit (QIAGEN). The relevant purified DNA samples of all the cases and controls will be amplified and sequenced using automated sequencing with the aid of a Big Dye Terminator Sequencing Kit (PE/Applied Biosystems, Foster City, CA). The samples will be run in an automated sequencer ABI Prism 310 Avant (PE/Applied Biosystems).. All samples will be sequenced twice to ensure the results.
Statistical analysis: Data will be statistically described in terms of mean standard deviation , median and range. Comparison between women who could achieve pregnancy and those who didn't was done using Mann Whitney U test for independent samples. Correlation between various variables was done using Spearman rank correlation equation for non-normal variables.
- Being tested
- Endometrial biopsy
- Keywords
- CYTOKINES , IL11 IL6 IMLANTATION RATE IVF.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endometrial biopsyProcedure or surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
relation between IL11 AND IL6 PRESENCE AND GENE EXPRESSION AND SUCCESS OF IVF
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2013 (estimated)
- Study startJan 2012
- Primary completionJun 2013 (estimated)
- Study completionNov 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Endometrial Receptivity and Success Rate of IVFStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Olfat Nooh Riad Ali, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01809509
- Sponsor's protocol ID
- FDAAA
- Status last verified
- Mar 2013
- First submitted
- 9 Mar 2013
- Last updated
- 12 Mar 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prestudy of Impact of Cytokines and Gene Expression on Outcome of IVF
- ClinicalTrials.gov ID
- NCT01809509
- Acronym / sponsor ID
- FDAAA
- Keywords
- CYTOKINES , IL11 IL6 IMLANTATION RATE IVF.
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- Jan 2012
- Primary completion
- Jun 2013 (estimated)
- Study completion
- Nov 2013 (estimated)
- First posted
- 12 Mar 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pilot study on molecular quantitation and sequencing of endometrial cytokines gene expression and their effect on the outcome of in-vitro fertilization (IVF) Cycle
Detailed description
The study will be performed
in the Cairo IVE Unit; Faculty of medicine Cairo University on 15 cases. Inclusion criteria: age 23 -35, FSH less than 10 no previous uterine operations, no history of poor response in previous IVF no sever male factor no endometriosis and uterine factor are excluded . no diabetes mellitus and antral follicle count (AFC) > 5 undergoing IVF using standard long protocol.
All patients will give their informed consent to participate in the study. Endometrial tissue samples will be taken on the day of oocyte retrieval using soft suction plastic catheter. The menstrual blood of 10 women with regular menstrual cycles and with no apparent endometrial dysfunction was taken as control samples. The study protocol and informed consents were approved by the Human Ethics Committee of IVF department .of Kasar Ini hospital
Total RNA isolation: Endometrial biopsies and menstrual control blood will be lysed by RLT buffer (QIAGEN, Germantown, MD). The lysates further prepared for total RNA extraction using the RNeasy mini kit (QIAGEN, Germantown, MD) according to the manufacturer's instructions. The RNA extract stored at -80ºC until future use. RNA purity, yield, and concentration will be determined through dual spectrophotometry (Beckman, USA), and 1μg of RNA run on a 1% agarose gel (Roche, Castle Hill, Australia) to ensure integrity of the RNA. Quantitative RT-PCR (qRT-PCR): Reverse transcriptase (RT) reaction mixture using High Capacity Reverse Transcriptase kit (Applied Biosystems, USA) containing: 1 μg total RNA from each sample for cDNA synthesis, 0.5 μg random primer, 5×RT buffer, 2.5 mmol/L dNTP, 20 U RNase inhibitor and 200 U MMLV reverse transcriptase in a total volume of 25 μl was incubated at 37ºC for 60 minutes, then heated to 95 ºC for 5 minutes to inactivate MMLV. RT will be followed by qPCR, 50 ng of cDNA were added to 5 X Fast-Start SYBR green master mix with Rox (Roche Diagnostics, Indianapolis, IN) and 200 ng of primer mix (Sigma). The reaction will be carried out in micro optical plates (Applied Biosystems) and analyzed using StepOne real-time 203 PCR system (Applied Biosystems). The PCR running method was as follows: 10 minutes at 950C for enzyme activation followed by 40 cycles of 15 seconds at 950C, 20 seconds at 550C and 30 second at 720C for the amplification step. The primers used in the qRT-PCR evaluation specific for target genes (table 1). Relative mRNA expression will be calculated by the comparative cycle threshold method . as outlined in the manufacturer's user manual with GAPDH house-keeping gene. The fluorescence was plotted versus PCR cycle number for reaction and each sample indicated. Serum hormonal levels assay: FSH, LH and E2 were estimated by ELISA according to instructions of manufacturers. DNA purification and sequencing analysis: IL-11 and LIF genes analyzed by direct sequencing of the PCR products using SEQr kit. (Applied Biosystems), according to manufacturer's protocol. PCR products will be purified using the QIAquick Gel Extraction Kit (QIAGEN). The relevant purified DNA samples of all the cases and controls will be amplified and sequenced using automated sequencing with the aid of a Big Dye Terminator Sequencing Kit (PE/Applied Biosystems, Foster City, CA). The samples will be run in an automated sequencer ABI Prism 310 Avant (PE/Applied Biosystems).. All samples will be sequenced twice to ensure the results.
Statistical analysis: Data will be statistically described in terms of mean standard deviation , median and range. Comparison between women who could achieve pregnancy and those who didn't was done using Mann Whitney U test for independent samples. Correlation between various variables was done using Spearman rank correlation equation for non-normal variables.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 23 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- those under going IVF using standard protocol
Key inclusion criteria (1 listed)
- FSH LESS THAN 10 ,
Key exclusion criteria (1 listed)
- NO SEVER MALE FACTOR no endometriosis , DM or previous uterine surgery .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endometrial biopsy | Procedure or surgery | – |
Primary outcome
relation between IL11 AND IL6 PRESENCE AND GENE EXPRESSION AND SUCCESS OF IVF
Time frame: one year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2013.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Endometrial Receptivity and Success Rate of IVF, run by Cairo University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
relation between IL11 AND IL6 PRESENCE AND GENE EXPRESSION AND SUCCESS OF IVF (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2013.